Cancer Mechanisms

项目摘要/摘要 Tisch癌症研究所(TCI)的癌症机制(CM)计划由49名成员组成，他们 有一个共同的目标，那就是催化与癌症相关的机制发现相关的基础研究 最终目标是产生新的知识，从而改善诊断、治疗和预防 在我们独特的集水区，通过三个关键主题对原发癌症和系统性癌症复发进行研究：1. 细胞和生态位生物学，2.细胞信号网络和3.染色质和基因 监管(见研究战略中的图1)。 CM的首席调查员代表15个部门和10个研究所。截至2019年2月，CM计划 成员获得了超过1700万美元的直接成本资金，其中NCI支持470万美元，同行- 回顾了1370万美元的癌症相关支持。2018年，该计划发表了82篇论文，其中22%是 内部和17%是方案间的。 我们的前提是基础研究集中在遗传、表观遗传、生化、微环境和 驱动原发癌症启动和维持的发育途径，最小残留疾病， 休眠和显性转移，将揭示新的生物标记物和治疗靶点，以解决这些问题 液体和固体肿瘤的分期。我们的目标是阐明三个CM的关键机制 主题并促进计划内和计划间的合作，以加速将发现转化为 翻译和临床方面的努力。我们将通过协调的方案内努力来实现这一目标 CM主题(例如，工作组、每月会议)以及与其他组织的方案间协作 癌症临床调查(CCI)、癌症预防与控制(CPC)和癌症 免疫学(CI)或疾病焦点组，如肝癌。特别是我们新的战略规划， 允许CM调查人员在确定用于治疗干预的目标、生物标志物或分子后进行工作 与新创建的CCI计划密切相关，该计划有助于加快转换或临床路径。 最后，我们的战略计划将促进新的合作研究、培训和教育机会 我们的计划和我们的社区(通过与CPC的努力)、高影响力的出版物、MPI/P01提交、 通过与CCI的合作以及其他团队努力，实现临床试验和转化成果，包括 CM的超凡科学。

PROJECT SUMMARY/ABSTRACT The Cancer Mechanisms (CM) Program of The Tisch Cancer Institute (TCI) is comprised of 49 members who share a common goal to catalyze basic research pertinent to cancer-relevant mechanistic discovery with the ultimate goal of generating new knowledge that will lead to improving the diagnosis, treatment, and prevention of primary cancer and systemic cancer recurrence in our unique catchment area across three key themes: 1. CELL AND NICHE BIOLOGY, 2. CELL SIGNALING NETWORKS and 3. CHROMATIN AND GENE REGULATION (see Figure 1 in the Research Strategy). Principal investigators in CM represent 15 Departments and 10 Institutes. As of February 2019, CM program members were awarded over $17 million in direct cost funding, with NCI support of $4.7 million and peer- reviewed cancer-related support of $13.7 million. In 2018, the program published 82 papers of which 22% were intra- and 17% were inter-programmatic. Our premise is that basic research focused on genetic, epigenetic, biochemical, micro-environmental, and developmental pathways that drive primary cancer initiation and maintenance, minimal residual disease, dormancy and overt metastasis, will reveal novel biomarkers and therapeutic targets to address each of these stages across both liquid and solid tumors. We aim to elucidate critical mechanisms across the three CM themes and foster intra- and inter-program collaborations in order to accelerate the transfer of discoveries into translational and clinical efforts. We will achieve this goal using orchestrated intra-programmatic efforts within CM themes (e.g. working groups, monthly meetings), and inter-programmatic collaborations with other programs such as Cancer Clinical Investigation (CCI), Cancer Prevention and Control (CPC) and Cancer Immunology (CI) or with disease focus groups such as Liver Cancer. In particular, our new strategic plan allows CM investigators, upon identifying targets, biomarkers or molecules for therapeutic intervention, to work closely with the newly created CCI program, which facilitates an accelerated translational or clinical path. Finally, our strategic plan will facilitate new collaborative research, training and education opportunities within our program and in our community (via efforts with CPC), high-impact publications, MPI/P01 submissions, clinical trials and translational output through partnership with CCI, and other team efforts that encompass CM's exceptional science.